Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP58: Human Leukocyte Antigen drives methylation signatures in primary sclerosing cholangitis but not in IgG4-related sclerosing cholangitis.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Motta, Rodrigo
Created: Tuesday, 30 April 2024, 5:03 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gili Focht
Created: Friday, 14 July 2023, 2:22 PM
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jasmijn Sleutjes
Created: Tuesday, 23 June 2020, 5:40 PM
DOP59: Integration of in silico analysis and in vitro functional analysis reveals Tissue Factor Pathway Inhibitor 2 (TFPI2) as a master transcriptional regulator and potential target to impede Infliximab resistance in adult UC patients
Year: 2024
Source: ECCO'24 Stockholm
Authors: Genua, Flavia
Created: Tuesday, 30 April 2024, 5:03 PM
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
Year: 2020
Source: ECCO'20 Vienna
Authors: Walter Reinisch
Created: Tuesday, 23 June 2020, 5:40 PM
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Christine Norton
Created: Friday, 14 July 2023, 2:22 PM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rupa Banerjee
Created: Friday, 14 July 2023, 2:22 PM
DOP60: Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gutiérrez Casbas, Ana
Created: Tuesday, 30 April 2024, 5:03 PM
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 5:40 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dan Turner
Created: Friday, 14 July 2023, 2:22 PM
DOP61: Tofacitinib, an oral, small molecule Janus kinase inhibitor, in the treatment of Ulcerative Colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
Year: 2020
Source: ECCO'20 Vienna
Authors: Donna Judd
Created: Tuesday, 23 June 2020, 5:40 PM
DOP61: Up-regulated Gremlin 1 in fibroblasts from Crohn’s Disease fibrotic strictures: A potential therapeutic target
Year: 2024
Source: ECCO'24 Stockholm
Authors: Santacroce, Giovanni
Created: Tuesday, 30 April 2024, 5:03 PM
DOP62: A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative Colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Saifuddin, Aamir
Created: Tuesday, 30 April 2024, 5:03 PM
DOP62: Medication use is increased in the decade prior to IBD diagnosis: A nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Linéa Bonfils
Created: Friday, 14 July 2023, 2:22 PM
DOP62: Morbidity after primary ileocecal resection for Crohn’s Disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
Year: 2020
Source: ECCO'20 Vienna
Authors: Matteo Rottoli
Created: Tuesday, 23 June 2020, 5:40 PM
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trial
Year: 2020
Source: ECCO'20 Vienna
Authors: Gionata Fiorino
Created: Tuesday, 23 June 2020, 5:40 PM
DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Jansson, Sabine
Created: Tuesday, 30 April 2024, 5:03 PM
DOP63: Time Trends of Environmental and Socio-economical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis revisited.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Péter Laszlo Lakatos
Created: Friday, 14 July 2023, 2:22 PM
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Jamie Wong
Created: Tuesday, 23 June 2020, 5:40 PM
DOP64: Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Raine, Timothy
Created: Tuesday, 30 April 2024, 5:03 PM